PPF/SOTIO Biotech Pipeline

So far SOTIO has sponsored 14 clinical trials. In addition, multiple projects in the portfolio are advancing through preclinical development and will soon enter the clinic. Through agreements with Cytune Pharma, NBE-Therapeutics and Lead Discovery Center, SOTIO has added more novel oncology programs to the SOTIO® product pipeline. SOTIO and its affiliated companies and partners collaborate to rapidly advance these programs to the clinical development stage and towards commercialization. Programs from these collaborations are currently moving through the preclinical stage with the aim to start Phase I clinical trials in the near future. SOTIO recently initiated a Phase I/Ib clinical trial with SO-C101, an interleukin-15 superagonist.

This website uses cookies; by continuing to use this page, you consent to their use. About cookies